Cargando…
The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation
Autores principales: | Khorana, Alok A., McCrae, Keith, Milentijevic, Dejan, McCormick, Nora, Laliberté, François, Crivera, Concetta, Lefebvre, Patrick, Lejeune, Dominique, Rozjabek, Heather, Schein, Jeff, Streiff, Michael B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590399/ https://www.ncbi.nlm.nih.gov/pubmed/30474161 http://dx.doi.org/10.1002/ajh.25361 |
Ejemplares similares
-
Duration of anticoagulant therapy and VTE recurrence in patients with cancer
por: Khorana, Alok A., et al.
Publicado: (2019) -
Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer
por: Streiff, Michael B., et al.
Publicado: (2018) -
Current practice patterns and patient persistence with anticoagulant treatments for cancer‐associated thrombosis
por: Khorana, Alok A., et al.
Publicado: (2017) -
Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels
por: Khorana, Alok A., et al.
Publicado: (2020) -
Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)